Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
swine influenza bivalent inactivated vaccine (H1N1 LN strain + H3N2 HLJ strain)
- Development stage
- Unknown
- Lead developer
- Sinovet Biopharmaceutical
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The swine influenza bivalent inactivated vaccine (H1N1 LN strain + H3N2 HLJ strain) is a veterinary biologic developed by Youbang Pharmaceutical for the prevention of swine influenza in pigs. The vaccine is formulated with two inactivated viral strains: the H1N1 LN strain (likely originating from Liaoning province) and the H3N2 HLJ strain (likely originating from Heilongjiang province). As a bivalent inactivated product, it is designed to stimulate the porcine immune system to produce protective antibodies against both H1N1 and H3N2 subtypes of the swine influenza virus. It is used as a prophylactic measure to control respiratory disease outbreaks in swine populations.
- Other names
- 猪流感二价灭活疫苗 (H1N1LN株 + H3N2HLJ株)Swine influenza bivalent inactivated vaccine (H1N1LN strain + H3N2HLJ strain)Swine influenza bivalent inactivated vaccine (H1N1 LN strain + H3N2 HLJ strain)-Youbang Pharmaceutical
02
Targets
SIV (Swine influenza A virus)
Beyond the preview
Go deeper on swine influenza bivalent inactivated vaccine (H1N1 LN strain + H3N2 HLJ strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on swine influenza bivalent inactivated vaccine (H1N1 LN strain + H3N2 HLJ strain).